MPMatthew Parnall

Matthew Parnall

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Matthew Parnall has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Development and validation of blood-based predictive biomarkers for response to PD-(L)-1 checkpoint inhibitors: Evidence of a universal systemic core of 3D immunogenetic profiling across multiple oncological indications.

    by Alexandre Akoulitchev, Ewan Hunter, Francisco C. Santos, Mehrnoush Dezfouli, Christina Koutsothanasi, Matthew Salter, Ryan Powell, Ann Dring, Benedict Egan, Matthew Parnall, et al.

    E14525 Background: Unprecedented advantages in cancer treatments with immune checkpoint inhibitors (ICI) remain limited to a subset of patients, with high demands for development of better biomarkers to access likely clinical response in advance of ICI therapeutic interventions. 3D genomics has emerged as a novel molecular biomarker modality with strong functional correlation to clinical outcomes (1). The last few years have seen rapid emergence of 3D genomics applications in clinical stratifications. They have demonstrated high sensitivity and specificity in patient stratifications, offered solutions in symptomatic and pre-symptomatic diagnosis, in prognosis, residual disease monitoring, and prediction of response to therapeutic interventions (2-8). EpiSwitch is a 3D genomic platform that has been reduced to practice for the discovery of 3D genomic blood-based biomarkers in a variety of immune-related and oncological diseases (7,8). Methods: A clinical blood assay based on 8 markers - Checkpoint Inhibitor Response Test (CiRT) - has been developed to predict response to PD-(L)1 immune checkpoint inhibition from over 30 million data points, with validations on several independent cancer patient cohorts. The predictive 8 biomarker set is based on an observational clinical trial and several retrospective cohorts, representing all together 229 treatments with Pembrolizumab, Atezolizumab, Durvalumab, in over 15 diverse oncological indications, i.e. melanoma, lung, urethral, hepatocellular, bladder, prostate, head and neck, colon, breast, bone, brain, lymphoma, larynx. Results: CiRT has demonstrated high accuracy up to 85%, sensitivity of 93% and specificity of 82%. Conclusions: This study demonstrates that a 3D genomic approach could be successfully utilized for development of a non-invasive predictive clinical assay for response to PD-(L)1 checkpoint inhibition in cancer patients. CiRT can assist in treatment decisions, help improve patient selection for optimized treatment, utilize alternative effective treatments, minimize unnecessary toxicity, and efficiently manage the costs.

  • Open Access

    Characterisation of the developing heart in a pressure overloaded model utilising RNA sequencing to direct functional analysis

    by Matthew Parnall, Chrysostomos Perdios, Kar Lai Pang, Sophie Rochette, Siobhan Loughna

    Cardiogenesis is influenced by both environmental and genetic factors, with blood flow playing a critical role in cardiac remodelling. Perturbation of any of these factors could lead to abnormal heart development and hence the formation of congenital heart defects. Although abnormal blood flow has been associated with a number of heart defects, the effects of abnormal pressure load on the developing heart gene expression profile have to date not clearly been defined. To determine the heart transcriptional response to haemodynamic alteration during development, outflow tract (OFT) banding was employed in the chick embryo at Hamburger and Hamilton stage (HH) 21. Stereological and expression studies, including the use of global expression analysis by RNA sequencing with an optimised procedure for effective globin depletion, were subsequently performed on HH29 OFT‐banded hearts and compared with sham control hearts, with further targeted expression investigations at HH35. The OFT‐banded hearts were found to have an abnormal morphology with a rounded appearance and left‐sided dilation in comparison with controls. Internal analysis showed they typically had a ventricular septal defect and reductions in the myocardial wall and trabeculae, with an increase in the lumen on the left side of the heart. There was also a significant reduction in apoptosis. The differentially expressed genes were found to be predominately involved in contraction, metabolism, apoptosis and neural development, suggesting a cardioprotective mechanism had been induced. Therefore, altered haemodynamics during development leads to left‐sided dilation and differential expression of genes that may be associated with stress and maintaining cardiac output.


  • Open Access

    Altered haemodynamics causes aberrations in the epicardium

    by Chrysostomos Perdios, Matthew Parnall, Kar Lai Pang, Siobhan Loughna

    During embryo development, the heart is the first functioning organ. Although quiescent in the adult, the epicardium is essential during development to form a normal four‐chambered heart. Epicardial‐derived cells contribute to the heart as it develops with fibroblasts and vascular smooth muscle cells. Previous studies have shown that a heartbeat is required for epicardium formation, but no study to our knowledge has shown the effects of haemodynamic changes on the epicardium. Since the aetiologies of many congenital heart defects are unknown, we suggest that an alteration in the heart's haemodynamics might provide an explanatory basis for some of them. To change the heart's haemodynamics, outflow tract (OFT) banding using a double overhang knot was performed on HH21 chick embryos, with harvesting at different developmental stages. The epicardium of the heart was phenotypically and functionally characterised using a range of techniques. Upon alteration of haemodynamics, the epicardium exhibited abnormal morphology at HH29, even though migration of epicardial cells along the surface of the heart was found to be normal between HH24 and HH28. The abnormal epicardial phenotype was exacerbated at HH35 with severe changes in the structure of the extracellular matrix (ECM). A number of genes tied to ECM production were also differentially expressed in HH29 OFT‐banded hearts, including DDR2 and collagen XII. At HH35, the differential expression of these genes was even greater with additional downregulation of collagen I and TCF21. In this study, the epicardium was found to be severely impacted by altered haemodynamics upon OFT banding. The increased volume of the epicardium at HH29, upon OFT‐banding, and the expression changes of ECM markers were the first indicative signs of aberrations in epicardial architecture; by HH35, the phenotype had progressed. The decrease in epicardial thickness at HH35 suggests an increase in tension, with a force acting perpendicular to the surface of the epicardium. Although the developing epicardium and the blood flowing through the heart are separated by the endocardium and myocardium, the data presented here demonstrate that altering the blood flow affects the structure and molecular expression of the epicardial layer. Due to the intrinsic role the epicardium in cardiogenesis, defects in epicardial formation could have a role in the formation of a wide range of congenital heart defects.


  • Open Access

    Cardiac troponin T is necessary for normal development in the embryonic chick heart

    by Jennifer England, Kar Lai Pang, Matthew Parnall, Maria Isabel Haig, Siobhan Loughna

    The heart is the first functioning organ to develop during embryogenesis. The formation of the heart is a tightly regulated and complex process, and alterations to its development can result in congenital heart defects. Mutations in sarcomeric proteins, such as alpha myosin heavy chain and cardiac alpha actin, have now been associated with congenital heart defects in humans, often with atrial septal defects. However, cardiac troponin T (cTNT encoded by gene TNNT2) has not. Using gene‐specific antisense oligonucleotides, we have investigated the role of cTNT in chick cardiogenesis. TNNT2 is expressed throughout heart development and in the postnatal heart. TNNT2‐morpholino treatment resulted in abnormal atrial septal growth and a reduction in the number of trabeculae in the developing primitive ventricular chamber. External analysis revealed the development of diverticula from the ventricular myocardial wall which showed no evidence of fibrosis and still retained a myocardial phenotype. Sarcomeric assembly appeared normal in these treated hearts. In humans, congenital ventricular diverticulum is a rare condition, which has not yet been genetically associated. However, abnormal haemodynamics is known to cause structural defects in the heart. Further, structural defects, including atrial septal defects and congenital diverticula, have previously been associated with conduction anomalies. Therefore, to provide mechanistic insights into the effect that cTNT knockdown has on the developing heart, quantitative PCR was performed to determine the expression of the shear stress responsive gene NOS3 and the conduction gene TBX3. Both genes were differentially expressed compared to controls. Therefore, a reduction in cTNT in the developing heart results in abnormal atrial septal formation and aberrant ventricular morphogenesis. We hypothesize that alterations to the haemodynamics, indicated by differential NOS3 expression, causes these abnormalities in growth in cTNT knockdown hearts. In addition, the muscular diverticula reported here suggest a novel role for mutations of structural sarcomeric proteins in the pathogenesis of congenital cardiac diverticula. From these studies, we suggest TNNT2 is a gene worthy of screening for those with a congenital heart defect, particularly atrial septal defects and ventricular diverticula.